title: [Motor levodopa-induced complications in Parkinson's disease].
abstract: Chronic treatment with levodopa in Parkinson's disease (PD) is associated with the risk of development of motor fluctuations and dyskinesias, i.e. motor levodopa-induced complications (MLIC).
  
  
  OBJECTIVE
  The aim of the study was to investigate factors influencing prevalence of MLIC in PD patients.
  
  
  METHODS
  76 patients with idiopathic PD were included in the study. Theirs mean disease duration was 10,33 years and mean levodopa therapy duration was 8,65 years. The most common drug regimen was levodopa with ropinirole. The patients were evaluated using Hoehn and Yahr scale, UPDRS II, III, and were qualified for 4 clinical subtypes according to van Rooden at al. classification.
  
  
  CONCLUSIONS
  The prevalence of MLIC was 54% with their mean duration of 3,34 years. MLIC were influenced by higher levodopa equivalent dose, younger age at onset, younger age, longer disease duration, and longer levodopa therapy regardless of PD clinical subtype. Although women had more advanced disease according to Hoehn and Yahr score, sex did not influence MLIC. The incidence of MLIC in both sexes was probably leveled by inclusion of sex as a risk factor of MLIC in treatment strategy. Therefore modifiable MLIC risk factors should be investigated in different PD populations.
authors.affiliation: Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Michałowska
authors.affiliation: Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland.
authors.forename: Urszula
authors.initials: U
authors.lastname: Fiszer
authors.affiliation: Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Szatanowski
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000453:epidemiology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa
keywords: stress urine incontinence; urinary incontinence treatment; urodynamic study